MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
4.890
-0.290
-5.60%
Opening 14:21 12/05 EST
OPEN
5.15
PREV CLOSE
5.18
HIGH
5.18
LOW
4.881
VOLUME
3.85M
TURNOVER
--
52 WEEK HIGH
7.30
52 WEEK LOW
1.260
MARKET CAP
1.30B
P/E (TTM)
-5.0376
1D
5D
1M
3M
1Y
5Y
1D
Is Sana Biotechnology's (SANA) SC451 Pivot Quietly Redefining Its Long-Term Platform Strategy?
Simply Wall St · 2h ago
Weekly Report: what happened at SANA last week (1124-1128)?
Weekly Report · 4d ago
Sana Biotechnology (SANA): Evaluating Valuation After Recent Surge in Share Price
Simply Wall St · 6d ago
Will Sana Biotechnology’s (SANA) Pipeline Shift Redefine Its Long-Term Strategic Positioning?
Simply Wall St · 11/28 17:27
Sana Biotechnology to Webcast Presentations at Major Investor Conferences
Reuters · 11/24 21:05
Sana Biotechnology to Present at December 2025 Investor Conferences
Barchart · 11/24 15:05
Weekly Report: what happened at SANA last week (1117-1121)?
Weekly Report · 11/24 09:22
Top 3 Genomics Stocks to Consider for Your Portfolio
NASDAQ · 11/18 13:48
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.